Table 1. PICOS strategy for data extraction of novel glycopeptides.

PICOS	Clinical Review
Participants	Adult patients (18 years and older) of any gender with any confirmed or suspected bacterial infections caused by gram-positive cocci including MRSA.
Intervention	Any novel glycopeptides used in the management of gram-positive bacterial infections will be considered eligible. The antibiotics include: Telavancin, dalbavancin and oritavancin.
Comparator	Vancomycin
Outcome	Clinical treatment success (resolution of clinical signs and symptoms of infections), microbiological treatment success (eradication of bacteria), adverse events, serious adverse events, discontinuation due to adverse events and mortality.
Study design	Randomized controlled trials.

Abbreviation: MRSA: Methicillin resistance Staphylococcus aureus.